However, the stock looks very cheap when looking at the price-to-sales per share multiple.
FORBES: Jumping Into The Cage With THQ For At Least A 12% Gain
Historically speaking, the market has been willing to pay between 1.22x and 3.54x times sales per share.
Trading for close to 10x sales per share means that the market has already priced-in a substantial growth factor.
FORBES: Illuminating Thought: Cree Is Not Terribly Expensive
But as we tried to demonstrate with price-to-sales per share, the market has already baked in quite a growth premium.
FORBES: Illuminating Thought: Cree Is Not Terribly Expensive
Furthermore, a current price-to-sales per share multiple of only 0.31x is well below the historically normal range of 0.36x and 0.71x.
Similarly, with price-to-sales per share around 3.5x, it is near the historical high end of the range at 2.2x to 3.6x.
FORBES: Fastenal's Drop On Hefty Earnings Gain Is No Reason To Buy
The historically normal range of price-to-sales per share is .76x to 1.51x, but coming into the day it was only .86x.
Similarly, price-to-sales per share is currently 3.8x, which is approaching the high end of the historically normal range of 2.6x to 4.3x.
But although sales per share rose rapidly during the second half of the decade now ended, the share price itself did not.
Furthermore, trading at 2.14x sales per share, BMY looks like a deal compared to the historically normal range of 2.05x to 3.02x times sales per share.
Likewise, some might view a price-to-sales per share multiple of 3.2x as excessive, but historically speaking the market has been willing to pay between 5.7x and 11.1x.
Historically speaking, the market has been willing to pay 3.3x to 7.5x times sales per share, but at current levels it trades at a price-to-sales level of 9.6x.
FORBES: Illuminating Thought: Cree Is Not Terribly Expensive
Coming into the day, BGP was trading for just .05x sales per share, which is well below the historically normal price-to-sales valuation range for BGP of 0.17x to 0.33x.
The stock currently trades at .84x times sales per share, which is within the historically normal price-to-sales per share range of .73x to 1.02x but closer to the low end.
For example, AMD currently trades for a price-to-sales per share of 1.00x which is on the low end of the historically normal range of .75x to 2.27x for this valuation metric.
Looking at the historical valuation, BEZ has normally traded between .72x and 1.22x sales per share, and the current metric is on the high side of that at 1.11x as well.
For example, at the low end of the estimate CSTR would trade for .97x sales per share, while the market has historically been willing to pay between 1.14x and 2.03x times sales per share.
Over the last ten years, THQ has historically fetched between 0.72 and 1.76 times revenue per share, but using the middle of the new sales guidance, THQ is selling for only 0.39x times sales per share.
FORBES: Jumping Into The Cage With THQ For At Least A 12% Gain
To be fair, price-to-sales per share is currently within the historical valuation range, but it remains to be seen how sales will do after net closings of 44 US stores through the end of the fiscal year.
Over the last ten years, MDT grew both sales and earnings per share at 14% a year.
For the past 25 years sales and earnings per share have grown an annual 29% and 17%, respectively.
After its fiscal year ended in July 31, 2012, Pall released a fourth quarter and full year fiscal report in September, which revealed increases in such areas as sales and earnings per share.
FORBES: Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter
However, thanks to a more favorable sales mix, earnings per share should jump 14-18%.
The company reports its second quarter on Aug. 4, with analysts expecting profit to increase 22% to 44 cents per share on sales growth of 51%.
Merck and Schering-Plough both beat analyst projections for adjusted earnings by a whopping 8 cents per share on sales of cholesterol drug Vytorin, which they sell together, and separate allergy blockbusters Singular and Nasonex.
Big-box retailer Target reported its second-quarter sales jumped 14.3% to 92 cents per share, in line with expectations despite weaker-than-expected sales, thanks to cost-cutting.
The measurements varied widely, ranging from sales to return on equity to earnings per share.
Sales were up 11% and earnings per share were up 15%--better than most stateside drug companies have managed.
It said the dollar's relative strength hurt quarterly earnings by 5 cents per share and also suppressed sales growth.
Bristol also announced that its sales rose 10%, and earnings per share came in at 41 cents, excluding one-time items--two cents more than analysts' projections.
应用推荐